Literature DB >> 15334548

High-resolution 19p13.2-13.3 allelotyping of breast carcinomas demonstrates frequent loss of heterozygosity.

Tseng-Long Yang1, Yen-Rey Su, Chiun-Sheng Huang, Jyh-Cherng Yu, Yen-Li Lo, Pei-Ei Wu, Chen-Yang Shen.   

Abstract

In breast cancer, a high frequency of genomic deletion is found in chromosomal region 19p13. Of particular interest is that the LKB1 gene (also known as STK11) has been mapped to this region. LKB1 is responsible for Peutz-Jeghers syndrome (PJS), a genetic disease characterized by mucocutaneous pigmentation and gastrointestinal hematoma with an increased risk of developing cancer, including breast cancer. To further clarify the role of chromosomal region 19p13.2-13.3 in the pathogenesis of breast cancer and to identify more precisely candidate tumor-suppressor genes (TSGs) for positional cloning studies, we performed detailed high-resolution allelotyping analysis to detect allelic loss or loss of heterozygosity (LOH) in this region on microdissected samples from 140 primary breast tumors using 24 microsatellite markers. The highest frequencies of LOH were seen with D19S883 (30%) and D19S216 (29%), both at 19p13.3, D19S922 (28%), at 19p13.3-19p13.2, and D19S865 (39%), at 19p13.2; in addition, identification was made of at least four common deletion regions, including the LKB1 locus, that are centered on these four markers. In all the cases, we found discontinuous allele loss at several 19p13.2-13.3 sites in the same tumor (with the markers with the highest frequency of LOH adjacent to markers retaining heterozygosity), suggesting the presence of multiple TSGs. Interestingly, in tumors, the extent of allelic loss at these markers (measured as the fractional allele loss) increased significantly as the tumors progressed to poorer grades (P < 0.05). We conclude that 19p13.2-13.3 allele loss is a common event in the pathogenesis of breast carcinoma that often involves discontinuous LOH of multiple, localized TSGs (including LKB1), the concurrent inactivation of which may contribute to breast cancer progression. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15334548     DOI: 10.1002/gcc.20080

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

Review 1.  LKB1 signaling in advancing cell differentiation.

Authors:  Lina Udd; Tomi P Mäkelä
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

Review 2.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

Review 3.  The mTOR pathway in breast cancer.

Authors:  Nancy E Hynes; Anne Boulay
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

4.  Mouse mammary tumor viral env sequences are not present in the human genome but are present in breast tumors and normal breast tissues.

Authors:  Steven Lehrer; Peter H Rheinstein
Journal:  Virus Res       Date:  2019-04-03       Impact factor: 3.303

5.  Polymorphisms of the apoptosis-associated gene DP1L1 (deleted in polyposis 1-like 1) in colon cancer and inflammatory bowel disease.

Authors:  Axel Wellmann; Franz Fogt; Stephan Hollerbach; Jens Hahne; Kerstin Koenig-Hoffmann; Daniela Smeets; Ulrich Brinkmann
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-19       Impact factor: 4.553

6.  LKB1 catalytic activity contributes to estrogen receptor alpha signaling.

Authors:  Suchita Nath-Sain; Paola A Marignani
Journal:  Mol Biol Cell       Date:  2009-04-15       Impact factor: 4.138

7.  MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer.

Authors:  Umadevi Thirumurthi; Jia Shen; Weiya Xia; Adam M LaBaff; Yongkun Wei; Chia-Wei Li; Wei-Chao Chang; Chung-Hsuan Chen; Hui-Kuan Lin; Dihua Yu; Mien-Chie Hung
Journal:  Sci Signal       Date:  2014-07-29       Impact factor: 8.192

8.  Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.

Authors:  Anju Singh; Vikas Misra; Rajesh K Thimmulappa; Hannah Lee; Stephen Ames; Mohammad O Hoque; James G Herman; Stephen B Baylin; David Sidransky; Edward Gabrielson; Malcolm V Brock; Shyam Biswal
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

9.  RanBP3 enhances nuclear export of active (beta)-catenin independently of CRM1.

Authors:  Jolita Hendriksen; Francois Fagotto; Hella van der Velde; Martijn van Schie; Jasprien Noordermeer; Maarten Fornerod
Journal:  J Cell Biol       Date:  2005-11-28       Impact factor: 10.539

10.  Low expression of adenomatous polyposis coli 2 correlates with aggressive features and poor prognosis in colorectal cancer.

Authors:  Yan Sun; Hua Tian; Xuehu Xu; Lin Wang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.